Furthermore, investigations on whether certain treatments are particularly effective in IRF8-high expressing AMLs, as proposed for tamibarotene [20], could increase knowledge about the role IRF8 in AML, and its usability as biomarker. The gene discussed is IRF8; the disease is acute myeloid leukemia.